ME/CFS: From Neglect to New Hope

Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS is a serious, life-altering disease that affects over 400,000 people in the UK, with many more living with ME-like symptoms following infections such as COVID. For patients and families, the impact can be enormous: persistent exhaustion, post-exertional malaise, pain, cognitive dysfunction, and in the most severe cases, being housebound, bedbound or unable to manage daily living tasks. And yet, awareness about what it is lags behind, let alone treatment options. In this episode of Biology Matters, Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME has remained so under-recognised, despite its scale and severity. Sonya explains that the disease often makes people invisible, because those most affected may be too unwell to leave their homes, attend appointments, work, study or maintain social contact. The conversation explores the importance of advocacy, collaboration and patient involvement in changing that reality. What You'll Learn: ● What ME is and why post-exertional malaise is such a defining feature of the disease ● Why ME and ME-like symptoms after COVID affect such a large number of people in the UK ● How invisibility and isolation shape the patient experience ● Why advocacy for ME depends on listening, collaboration and persistence ● How patient involvement can make research stronger and more trusted ● Why the economic case for better ME research and care is so significant ● How DecodeME, the LOCOME project, and precision medicine approaches are changing what is possible ● Why dedicated funding could accelerate diagnostics, drug repurposing and clinical progress Chapters 00:00 Introduction and meeting Sonya Chowdhury 01:49 What ME is and how many people it affects 02:49 Why ME can steal people’s lives 04:12 Why recognition and care have been so difficult 07:00 Sonya’s path from social work to patient advocacy 10:16 Why ME can remain hidden from public view 13:28 The economic impact of ME and ME-like symptoms 16:33 Why there are reasons to be hopeful 21:30 How DecodeME and LACOMI are changing the science 22:21 The small wins and the case for funding and policy action 29:07 What the UK needs to translate research into care 33:57 What ME can learn from other disease movements 35:55 Why £50 million could create real momentum 40:09 Why patient involvement makes research better 45:54 What patients need most from research and society 47:21 Why isolation matters and how visibility helps 51:03 Sonya’s five-year hope for ME, diagnostics and treatments 54:09 Final thoughts on collaboration and patient need Episode Resources: Sonya Chowdhury on LinkedIn:   / sonyachowdhury   Action for ME Website: https://www.actionforme.org.uk/ Steve Gardner on LinkedIn:   / stevegardner9999   PrecisionLife Website: https://precisionlife.com/ #MyalgicEncephalomyelitis #MECFS #ChronicFatigueSyndrome #PrecisionMedicine #LongCOVID #PostExertionalMalaise #ChronicDisease #MedicalResearch #PatientAdvocacy #BiologyMatters